CyclomicsSeq

About Cyclomics

Cyclomics is a private, early-stage diagnostics company developing innovative liquid biopsy solutions for cancer. Its core technology, CyclomicsSeq, combines molecular barcoding and consensus sequencing on the Nanopore platform to achieve high-accuracy (Q40) detection of rare mutations in blood. The company also offers Epinn, an AI-driven software framework for rapid tumor classification, and provides contract research services. Cyclomics is positioned to address the critical need for more sensitive, accessible, and faster molecular diagnostics in oncology.

Therapeutic Areas